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MicroRNAs (miRNAs) are small regulatory molecules
that control diverse biological processes that include
angiogenesis. Herpes simplex virus (HSV) causes a
chronic immuno-inflammatory response in the eye
that may result in corneal neovascularization during
blinding immunopathological lesion stromal keratitis
(SK). miR-132 is a highly conserved miRNA that is
induced in endothelial cells in response to growth
factors, such as vascular endothelial growth factor
(VEGF). In this study, we show that miR-132 expression
was up-regulated (10- to 20-fold) after ocular infection
with HSV, an event that involved the production of both
VEGF-A and IL-17. Consequently, blockade of VEGF-A
activity using soluble VEGF receptor 1 resulted in signif-
icantly lower levels of corneal miR-132 after HSV infec-
tion. In addition, low levels of corneal miR-132 were
detected in IL-17 receptor knockout mice after HSV in-
fection. In vivo silencing of miR-132 by the provision of
anti-miR-132 (antagomir-132) nanoparticles to HSV-in-
fected mice led to reduced corneal neovascularization
and diminished SK lesions. The anti-angiogenic effect of
antagomir-132 was reflected by a reduction in angio-
genic Ras activity in corneal CD31-enriched cells (pre-
sumably blood vessel endothelial cells) during SK. To
our knowledge, this is one of the first reports of miRNA
involvement in an infectious ocular disease. Manipulat-
ing miRNA expression holds promise as a therapeutic
approach to control an ocular lesion that is an impor-
tant cause of human blindness. (Am J Pathol 2012, 181:
525–534; http://dx.doi.org/10.1016/j.ajpath.2012.04.014)
Herpes simplex virus (HSV) causes a chronic immuno-
inflammatory response in the eye that is a significantcause of human blindness.1 The blinding lesion repre-
sents a T-cell–orchestrated reaction in the corneal
stroma set off by the infection.2 These stromal keratitis
(SK) lesions involve cellular and cytokine events that re-
semble those seen in some autoimmune diseases, and
control measures found effective in autoimmunity often
similarly act to control SK. One major feature of SK that is
not usually a prominent part of an autoimmune lesion is
pathological angiogenesis.3 Thus, the corneal site where
SK occurs is normally an avascular tissue, which is a
requisite for normal vision. Once corneal neovasculariza-
tion (CV) has occurred, inflammatory cells can easily gain
access to the eye, vision is impaired, and blood vessels,
once formed, are difficult to remove.2 Hence, a major
objective of therapies to control SK and several other
ocular lesions is to prevent or control the extent of neo-
vascularization.4 Several approaches have been evalu-
ated to achieve this objective, but none have proved to
be fully effective; alternative strategies are needed. Con-
ceivably, controlling the expression of one or more spe-
cies of microRNAs (miRNAs) is one such strategy. Thus,
several recent studies have indicated that miRNAs are
exploitable gene regulators, and many of them may be
dysregulated during tissue-damaging inflammatory reac-
tions and during pathological angiogenesis.5,6 Of partic-
ular interest, miR-132 acted as a switch to activate em-
bryonic human vascular endothelial cells to undergo
vasculogenesis.7 The miR-132 was also up-regulated
during pathological angiogenesis in a tumor model, and
inhibiting miR-132 by antagomir nanoparticles was inhib-
itory to tumor angiogenesis.7
The role for miRNA in tissue damage and angiogenesis
caused by an infectious agent is poorly understood.
Some recent reports, however, have indicated that
miRNA encoded by a virus can play a role in the expres-
sion of latency8 and the induction of tumors9 and may be
involved in human cytomegalovirus immune evasion.10
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tentially valuable approach for the control of the CV that
occurs during SK. Accordingly, miR-132 expression is
up-regulated after infection, and blockade of vascular
endothelial growth factor (VEGF)-A activity resulted in
significantly lower corneal miR-132 levels. Of particular
interest, IL-17 receptor knockout (RKO) mice produced
less miR-132 in corneas after infection. In addition, the
administration of antagomir-132 nanoparticles led to di-
minished angiogenic Ras activity that was reflected by
significantly reduced angiogenesis and diminished SK
lesions. The results of these studies indicate that manip-
ulating miRNAs, as shown herein by targeting miR-132,
might provide an additional avenue for the control of an
important cause of vision loss.
Materials and Methods
Mice
Female 6- to 8-week-old C57BL/6 mice were obtained
from Harlan Sprague Dawley Inc. (Indianapolis, IN). IL-
17RKO mice on a C57BL/6 background were obtained
from Amgen (Thousand Oaks, CA). The animals were
housed in American Association of Laboratory Animal
Care–approved facilities at the University of Tennessee,
Knoxville. All investigations followed the guidelines of the
institutional animal care and use committee.
Virus
HSV-1 strain RE Tumpey was propagated in Vero cell
monolayers (ATCC no CCL81). Virus was grown in Vero
cell monolayers (ATCC, Manassas, VA), titrated, and
stored in aliquots at 80°C until used.
Corneal HSV-1 Infection and Scoring
Corneal infections of mice were performed under deep
anesthesia. The mice were lightly scarified on their cor-
neas with a 27-gauge needle, and a 3-L drop containing
104 plaque-forming units of HSV-1 RE Tumpey was ap-
plied to one eye. The development of SK lesion severity
and angiogenesis in the eyes of mice was examined by
slit-lamp biomicroscopy (Kowa Company, Nagoya, Japan).
The scoring system used was as follows: 0, normal cornea;
1, mild corneal haze; 2, moderate corneal opacity; 3, severe
corneal opacity; 4, opaque cornea and ulcer; and 5, cor-
neal rupture. The severity of angiogenesis was recorded
as previously described.11 According to this system, a
grade of four for a given quadrant of the circle represents
a centripetal growth of 1.5 mm toward the corneal center.
The score of the four quadrants of the eye was then
summed to derive the neovessel index (range, 0 to 16) for
each eye at a given time point.
Subconjunctival Injections
Subconjunctival injections were performed as previously
reported.12 Briefly, these injections were performed using a2-cm, 32-gauge needle and syringe (Hamilton, Reno, NV) to
penetrate the perivascular region of conjunctiva, and the
appropriate amount of soluble VEGF receptor 1 protein/
isotype or scrambled sequences/antagomir-132 nanopar-
ticles was administered into the subconjunctival space.
Antagomir Sequences
Anti-miR-132 and scrambled sequences were procured
from Ambion (Austin, TX) and used as previously reported.7
Nanoparticle Preparation
Optimized histidine-lysine polymers have been applied
for small-interfering RNA deliveries in vitro and in vivo.13
One HK polymer species, H3K4b, having a lysine back-
bone with four branches containing multiple repeats of
histidine and lysine, was used for packaging small-inter-
fering RNAs against miR-132 or scrambled sequences,
with a nanoparticle to sequence ratio of 4:1 by mass. The
nanoparticles (average size, 150 nm in diameter) were
self-assembled, and these histidine-lysine polymers–
small-interfering RNA nanoparticles were used in mice.
Murine Treatment with Antagomir-132
Nanoparticles
Mice ocularly infected with HSV-1 RE Tumpey were sep-
arated into two groups. Antagomir-132 nanoparticle treat-
ment was begun at day 2, with additional doses on alter-
nate days until day 13 after infection. In another group of
experiments, the antagomir-132 treatment was started at
day 7 or day 10, with additional doses on alternate days
until day 13 after infection. The control group received
nanoparticles containing scrambled sequences subcon-
junctivally with the same regimen for respective experi-
ments. These animals were carefully followed for the pro-
gression of angiogenesis and SK development. All
experiments were repeated two times.
Purification of CD31-Enriched Cells
Purification of CD31-enriched cells (presumably endo-
thelial cells) from HSV-infected corneas was performed
as previously described.14 Briefly, the excised corneas
were pooled and digested with 60 U/mL Liberase for 35
minutes at 37°C in a humidified atmosphere of 5% CO2.
A single-cell suspension was prepared and stained with
anti-CD31–fluorescein isothiocyanate for 30 minutes on ice,
and fluorescein isothiocyanate–positive CD31 cells were
sorted using a fluorescence-activated cell sorter. Purity to
an extent of 80% to 90%was achieved. These sorted CD31-
enriched cells were used for pull-down assays.
Flow Cytometry
Corneal single-cell suspensions were prepared after Lib-
erase digestion of corneas. These corneal cell suspen-
sions were then stained for different cell surface mole-
cules. Briefly, cell suspensions were incubated with
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Gr1-phosphatidylethanolamine (1A8), CD4-allophyco-
cyanin (RM4.5), and CD31–fluorescein isothiocyanate
(BD Biosciences) for 30 minutes on ice. Thereafter, cells
were washed three times and resuspended in 1% para-
formaldehyde. Stained samples were acquired with an
FACS Calibur (BD Biosciences), and the data were ana-
lyzed using FlowJo software.
qPCR Data
Total mRNA was isolated from corneal cells using TRIzol
LS reagent (Invitrogen, Carlsbad, CA). The cDNA pre-
pared using 1 g of RNA was used for subsequent anal-
ysis. Quantitative PCR (qPCR) was performed using
SYBR Green PCR Master Mix (Applied Biosystems, Fos-
ter City, CA) with the iQ5 real-time PCR detection system
(Bio Rad, Hercules, CA). The expression levels of the target
genes were normalized to -actin with the CTmethod, and
relative quantification between control and infected mice
was performed using the 2-CT formula. The primers used
are as follows: Ras–glyceraldehyde-3-phosphate (GAP),
5=-GAGAAGAAGATCCACACGAAGG-3= (forward) and 5=-
CTCCAGGAGTATTATCTGAGGG-3= (reverse); and -ac-
tin, 5=-CTACCTCATGAAGATCCTGACC-3= (forward) and
5=-GTCTAGAGCAACATAGCACAGC-3= (reverse).
TaqMan miRNA qPCR
The miRNAs were extracted from HSV-infected murine
corneas using the mirVana miRNA Isolation Kit (Ambion).
These extracted miRNAs were converted to cDNAs using
the TaqMan MicroRNA Reverse Transcription Kit (Ap-
plied Biosystems) and primers for miR-132 and miR-
133a. TaqMan MicroRNA Assays (Applied Biosystems)
for miR-132 and miR-133a were used to quantify these
microRNAs using a real-time PCR detection system (Ap-
plied Biosystems). Data were normalized to the internal
control small nucleolar RNA 202. miR-133a (which is gen-
erally expressed in muscle cells) was used as a negative
control for miRNA quantification from corneas.15
Neutrophil Depletion with Monoclonal
Antibodies
Depletion of neutrophils during SK was performed as
previously described.16,17 Mice ocularly infected with
HSV-1 RE Tumpey were separated into two groups. One
group of animals was administered 200 g of anti-Ly6G
monoclonal antibody (1A8; BioXcell, West Lebanon, NH)
i.p. on alternate days starting from day 7 until day 13 after
infection. Experiments were terminated on day 14 p.i.,
and corneal samples were collected for further analysis.
Animals in the control group were given isotype control
(IgG2b) Ab (LTF-2; BioXcell) following the same regimen.
These experiments were repeated two times.WB Analysis
The corneal cells were lysed and total protein in the
supernatants was quantified using the BCA protein
assay kit (Thermo Scientific, Waltman, MA). Samples
were denatured in Laemmli buffer and resolved by
SDS-PAGE, and proteins were transferred onto a poly-
vinylidene difluoride membrane. The membrane was
blocked with 5% bovine serum albumin in Tris-buffered
saline with Tween 20 at 4°C overnight and subjected to
incubation with specific primary and secondary anti-
bodies. Protein bands were visualized using chemilu-
minescent horseradish peroxidase substrate (Milli-
pore, Billerica, MA). After keeping in stripping buffer
for 10 minutes, the membrane was reprobed using
anti--actin antibody. The antibodies used were as
follows: mouse Ras (Thermo Scientific), anti--actin
(C4), anti-Ras-GAP (B4F8), mouse anti-VEGF-A (EE02),
goat anti-mouse IgG–horseradish peroxidase, and
donkey anti-goat IgG–horseradish peroxidase. (All
these antibodies were procured from Santa Cruz Bio-
technology).
Ras Activation Assay
Ras activation assays were performed using an active Ras
pull-down and detection kit (Thermo Scientific), according
to the manufacturer’s protocol. Briefly, resin slurry was
added to the spin cup in a collection tube, and 100 g of
glutathione S-transferase GGA3-PBD fusion protein with
800 g of total protein (corneal cell lysate) was added to
this slurry. This was incubated at 4°C for 1 hour; finally, 50
L of reducing sample buffer was added and GTP-Ras
was pulled down and subsequently analyzed by using
Western blot (WB) analysis. These experiments were re-
peated two times.
Viral Plaque Assay
Virus titers were measured in the eye swabs taken from
HSV-infected mice using plaque assays, as previously
described by others.18
Statistics
The statistical significance for SK lesion severity and an-
giogenesis between two groups was determined using
an unpaired two-tailed Student’s t-test. A one-way anal-
ysis of variance, with Bonferroni’s post hoc test, was used
to calculate the level of significance for some experi-
ments. For all statistical analysis, GraphPad Prism soft-
ware was used.
Results
miR-132 Is Up-Regulated in Murine Corneas
after Ocular Infection with Herpes Simplex Virus
To measure changes in miR-132 levels after ocular HSV
infection, tissues were collected at various times and
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of miR-132, but not control miR-133a, were evident by
day 2 after infection (p.i.) in infected samples, with peak
expression levels evident in day 7 and day 14 p.i. sam-
ples (Figure 1, A and B). Uninfected scratch controls at
the same time points showed no changes in the levels of
miR-132 (data not shown). These data demonstrated that
miR-132 expression was elevated at multiple time points
after ocular HSV infection.
Blockade of VEGF-A Activity Diminishes Corneal
miR-132 Levels During SK
The increased expression of miR-132 at time points when
virus was cleared from the eyes and CV became evident
(usually by day 7 p.i.), which raised the issue as to the
triggers responsible for miR-132 up-regulation. Because
VEGF-A levels were increased after HSV infection and
remained so throughout the disease syndrome,17
VEGF-A was suspected to be an agonist for miR-132
up-regulation. Moreover, VEGF-A can induce miR-132
expression in the human umbilical vein endothelial cells.7
To investigate the role for VEGF-A, we measured the
effect of VEGF-A blockade on the expression of miR-132
levels. To effect VEGF-A blockade, animals were treated
after infection with 5 g VEGF trap (soluble VEGF recep-
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Figure 1. Expression of miR-132 after HSV infection. miRNA quantification in
HSV-infected mice corneas. WTmice are infected with HSV-1 RE in one eye, and
six corneas are collected and pooled for miRNA analysis by TaqMan qPCR. The
expression levels of miR-132 (A) and miR-133a (B) at different time points after
HSV infection in mice corneas are shown (pooled n  6 mice per group). A
one-way analysis of variance, with Bonferroni’s post hoc test, is used to calculate
the level of significance. *P 0.05, **P 0.01. Data represent mean SEM. The
previously described experiments are repeated three times.tor 1) or isotype control on alternate days, starting fromday 2 up to day 12 p.i. These conditions previously mark-
edly suppressed VEGF-A protein activity and also signif-
icantly inhibited CV.17 The corneas were collected at day
7 and day 14 p.i., and miR-132 levels were compared in
isotype control and VEGF trap-treated animals. When
compared with uninfected scratch controls, the miR-132
levels were elevated at day 7 p.i. in isotype-treated ani-
mals. However, miR-132 in the recipients of the VEGF
trap were, on average, fourfold less than in isotype-
treated animals (Figure 2A). The same pattern was evi-
dent at day 14 p.i. in mice treated with VEGF trap com-
pared with isotype-treated animals (Figure 2A).
In another set of experiments, neutrophils were de-
pleted16 during the clinical stage of SK (Figure 2B). Neu-
trophils are a source of VEGF-A, and their depletion re-
sults in lower VEGF-A levels in corneas obtained from
HSV-infected mice.17 Depletion (using 200 g of anti-
Ly6G antibody) was begun at day 7 p.i., with additional
doses on alternate days up to day 13. Neutrophil deple-
tion was clearly evident in the spleen and corneas of
HSV-infected mice treated with anti-Ly6G antibody (see
Supplemental Figure S1, A–C, at http://ajp.amjpathol.org).
Expression levels of miR-132 were compared in corneal
pools from depleted and isotype control mice on day
14 p.i. VEGF-A levels were reduced after depletion of
neutrophils in these experiments (Figure 2C). As shown in
Figure 2D, miR-132 expression levels were reduced by,
on average, threefold in the neutrophil-depleted mice
compared with isotype-treated animals. Taken together,
the two approaches supported the notion that VEGF-A
could be responsible for the up-regulation of miR-132
expression during HSV-induced CV.
Diminished Levels of miR-132 in IL-17RKO Mice
after HSV Infection
Our recent observations that mice unable to respond to
IL-17A showed reduced corneal VEGF-A levels19 led us
to investigate the possible role of IL-17A on miR-132
expression after HSV infection. To this end, IL-17A RKO
mice or wild-type (WT) mice were infected with HSV;
miR-132 levels were measured at days 2, 7, and 14 p.i.,
whereas Ras-GAP levels (miR-132 target) were mea-
sured at day 7 p.i. The significant increase in the levels of
Ras-GAP was evident in IL-17RKO mice (Figure 2E). As
shown in Figure 2, F and G, IL-17RKO mice showed
reduced CV and SK lesions compared with WT animals.
In addition, when miR-132 levels were measured in the
infected corneas at days 7 and 14 p.i., IL-17RKO mice
showed a twofold reduction in miR-132 levels compared
with WT mice (Figure 2H). The results from these exper-
iments indicated that the cytokine IL-17A was involved in
miR-132 up-regulation after HSV infection.
In Vivo Silencing of miR-132 by Antagomir-132
Nanoparticles Reduces Angiogenic Ras 1
in Corneas
Experiments were performed using nanoparticles con-
taining an antagomir for miR-132 or scrambled se-
nd 14 p
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AJP August 2012, Vol. 181, No. 2quences to determine the effect of antagomir treatment
on miR-132 levels in postinfection corneas. A dose of 2.5
g of antagomir-132 provided significant miR-132 knock-
down when measured at day 7 p.i. (Figure 3, A and B).
Because miR-132 targets Ras-GAP mRNA,7 levels of
both Ras-GAP mRNA and protein were measured. These
levels were elevated in mice treated with antagomir-132
nanoparticles compared with scrambled sequence re-
cipients (Figure 3, C and D).
Additional experiments were performed to measure
expression of active Ras 1 after in vivo knockdown in
infected animals, because miR-132 promoted VEGF sig-
naling by influencing active Ras levels in human umbilical
vein endothelial cells.7 Mice infected with HSV were
given 2.5 g of antagomir-132, or scrambled sequences,
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Ras-GAP mRNA analysis at day 7 (D7) p.i. (E) and miR-132 analysis by TaqM
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All experiments are repeated two times. *P  0.05, **P  0.01.subconjunctivally, starting from day 2 p.i., with additionaldoses on alternate days until day 10 p.i. Active Ras 1 was
pulled down from 6 corneas collected from each group at
day 11 p.i. (Figure 4A). As shown in Figure 4, B and C,
total Ras 1 levels were similar in all groups, but an in-
crease in GTP-Ras 1 was evident in animals treated with
scrambled sequences compared with uninfected con-
trols. In contrast, a reduction in GTP-Ras 1 was observed
in the antagomir-132 treatment group. In addition, active
Ras 1 pulled down from the CD31-enriched cells (pre-
sumably blood vessel endothelial cells) sorted from
scrambled sequences or antagomir-132–treated mice
corneas at day 11 p.i. revealed a reduction in active Ras
1 in antagomir-132–treated mice (see Supplemental Fig-
ure S2, D and E, at http://ajp.amjpathol.org). Curiously,
there was no difference in VEGF-A levels between these
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infected mice reduced the angiogenic Ras 1 activity but
did not affect VEGF-A levels in the corneas.
Provision of Antagomir-132 Nanoparticles
Diminishes Corneal Neovascularization
To evaluate the effect of inhibiting miR-132 expression on
the extent of angiogenesis induced after infection, ani-
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Figure 3. Knockdown of miR-132 by antagomir-132 nanoparticles in eyes.
A: The different doses of antagomir-132/scrambled sequences nanoparticle
treatment are given to HSV-infected mice, as shown. The 2.5-g antagomir-
132 treatment regimen results in peak miR-132 knockdown in the corneas (B)
(pooled n  6 mice per group). A one-way analysis of variance, with
Bonferroni’s post hoc test, is used to calculate the level of significance. *P 
0.05. These experiments are repeated two times. WT mice are infected with
HSV-1 RE in one eye, and six corneas are collected and pooled for analysis
by qPCR or WB. The 2.5-g antagomir-132/scrambled sequences are injected
subconjunctivally in HSV-infected mice, and the quantification of Ras-GAP
mRNA (C) from corneas isolated from different groups is performed (pooled
n  6 mice per group). The level of significance is determined by Student’s
t-test (unpaired). ***P  0.001. These experiments are repeated two times.
Data represent mean  SEM. Reducing WB for Ras-GAP protein after treat-
ment of HSV-infected mice with 2.5 g of antagomir-132/scrambled se-
quences (D) (pooled n  6 mice per group). The representative WB image
of two independent experiments is shown.mals were given an optimal dose subconjunctivally ofantagomir-132, or control nanoparticles, starting on either
treatment day 2 or day 7. As shown in Figure 5, A–C,
treatment begun on day 2 resulted in significantly re-
duced CV in the antagomir-treated animals and SK se-
verity was also significantly reduced. A visible reduction
in angiogenesis was evident in the eyes of mice treated
with antagomir-132 (see Supplemental Figure S2, A–C, at
http://ajp.amjpathol.org). An examination of collagen-di-
gested corneas at the termination of experiments on day 14
revealed that the number of inflammatory cells was signifi-
cantly diminished in the antagomir-132–treated group (Fig-
ure 5, D–I). We also measured the ocular viral titers on day
5 p.i. after administration of antagomir-132 or scrambled
sequences, and a slight increase in viral levels was evident
in antagomir-132–treated animals (see Supplemental Fig-
ure S3, A and B, at http://ajp.amjpathol.org).
In the experiments in which treatment was begun on
day 7 p.i., significantly diminished angiogenesis was also
evident in the antagomir-132–treated animals (Figure 6,
A–C). At the end of experiments on day 14, subpools of
corneal collagen digests were analyzed by flow cytom-
etry to enumerate the numbers of the CD31 cells (a
marker for vascular endothelial cells) and Gr1CD11b
cells (Figure 6, D–G). Both cell populations were signifi-
cantly reduced in number in the recipients of antagomir-
132 compared with those that received the scramble
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AJP August 2012, Vol. 181, No. 2sequence nanoparticles. In addition, the infiltration of
CD4 T cells was reduced in antagomir-132–treated an-
imals compared with scrambled sequence controls (Fig-
ure 6, H and I). Curiously, even when antagomir-132
treatment was started as late as day 10 p.i. (after estab-
lishment of blood vessels in eyes), this treatment modality
resulted in reduction in CV (see Supplemental Figure S3,
C–E, at http://ajp.amjpathol.org), but these changes were
not statistically significant. Taken together, our results
demonstrated that the silencing of miR-132 in the HSV-
infected eyes modulated the extent of angiogenesis and
the subsequent immunopathological characteristics that
occurred after HSV infection.
Discussion
Ocular HSV infection results in CV in the normally avas-
cular cornea. This represents a key event in the patho-
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trol pathological angiogenesis is a significant therapeutic
objective. Recently, it has become evident that the pro-
cess of neovascularization in tumors is influenced by
several miRNAs, particularly miR-132, that act to control
the response of vascular endothelial cells to angiogenic
factors, such as VEGF-A. We have evaluated the role of
miR-132 in an infectious disease model involving angio-
genesis, which represents an important cause of human
blindness. We show that miR-132 is up-regulated in the
corneas soon after infection, with levels remaining ele-
vated throughout the chronic inflammatory reaction
caused by the infection. The extent of CV could be sig-
nificantly diminished by local administration to the eye of
nanoparticles containing antagomirs that blunted the
miR-132 response. Furthermore, inhibition of CV could
still be achieved when the therapy was begun 7 days p.i.,
when CV was underway, with the chronic inflammatory
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AJP August 2012, Vol. 181, No. 2tion no longer present in the eye. However, inhibition of
CV was not complete after antagomir-132 treatment, and
it is possible that using additional approaches, along with
antagomirs, might be more successful. One critical event
influenced by miR-132 was the response of VEGFR2-
expressing vascular endothelial cells to VEGF-A, as was
recently described by Anand et al.7 miR-132 targeted
Ras-GAP, an endogenous inhibitor of Ras, which, when
activated, is responsible for causing vascular endothelial
cells to proliferate. In agreement with these observations,
we could show in our study that the administration of
miR-132 antagomirs diminished Ras activity in the CD31-
enriched cells (presumably blood vessel endothelial
cells). Our results indicate that modulating miRNA repre-
sents an effective approach to control CV, which reflects
in reducing the severity of SK lesions caused by HSV
infection. The results are summarized in Figure 7.
miRNAs are becoming well-known as regulators of im-
munity and inflammation, and manipulating their expres-
sion holds promise as a therapeutic maneuver.20 Few
studies have focused on the relevance of miRNA in the
control of pathological angiogenesis. However, it is be-
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a likely major role for miR-132 during angiogenesis be-
cause miRNA screens of embryonic vascular endothelial
cell (human umbilical vein endothelial cell) responses to
VEGF-A stimulation revealed that miR-132 expression
was the most elevated.7 Moreover, they could show that
normal expression of miR-132 was necessary for vascu-
lar development and that preventing its up-regulation
was beneficial in a tumor angiogenesis system.
Apart from the effects of miR-132 on angiogenesis, the
miRNA may also influence aspects of neural function,
which has occurred in some other systems.21–23 Because
the pathogenesis of HSV often involves stress-related
effects on a latent infection in the nervous system, it is
conceivable that regulation by miR-132 is involved in this
process. This issue merits further investigation.
In addition, rapid responses to some viruses, which
include HSV, may induce miR-132,24 although such re-
sponses are likely to represent innate reactions to the
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tor (TLR)-4 ligand may also cause the rapid expression of
miR-132 in macrophages in vitro.22 In our studies, we
noted early up-regulation (by 48 hours pi) of miR-132,
which might represent a response to the well-character-
ized TLR ligand activity of HSV.25,26 Preliminary in vitro
experiments support this interpretation (unpublished
data) and our past observations that TLR-2 and TLR-9
knockout mice have diminished CV compared with WT
animals, which is in line with the same interpretation.18
There are reasons, however, to consider that the direct
binding effects by virus to cells may not be the major
stimulus for miR-132 production, particularly by vascular
endothelial cells. Accordingly, in the mouse model, virus
replication is usually confined to the corneal epithelium,
but neovascularization occurs in the underlying stroma.2
Because miRNAs exert regulatory effects only in cells
that produce them, any effect of infection is expected to
be mediated indirectly via soluble molecules, such as
cytokines and cell breakdown products, generated dur-
ing the infection. Our data, along with the published re-
port of others,7 indicate that one agonist responsible for
causing miR-132 production in vascular endothelial cells
was VEGF-A. Evidence for this conclusion came from in
vivo observations that procedures that caused dimin-
ished VEGF-A production or activity resulted in reduced
levels of miR-132. For example, lowering VEGF-A levels
by a VEGF trap approach, or reducing the presence of
some cell types, such as neutrophils that produce
VEGF-A, resulted in diminished miR-132 levels. Perhaps
more convincing in favor of VEGF-A as responsible for
miR-132 production, we showed that animals treated with
nanoparticles containing miR-132 antagomirs had re-
Figure 7. Illustration of antagomir-132–mediated inhibition of CV. Left
panel:Outcome (CV) in HSV-infected untreated mice. HSV infection leads to
up-regulation of IL-17 in corneas. IL-17 (along with IL-6 and virus-infected
epithelial cells) increases VEGF (probably via increasing IL-1b, IL-6, and
Cxcl1) levels in the eyes. VEGF, thus acting through VEGFR2 receptors on the
blood vessel endothelial cells, up-regulates miR-132 expression via cAMP
response element–binding protein (CREB) transcription factor. miR-132 re-
moves Ras-GAP (intrinsic inhibitor of Ras), leading to activation of Ras and
CV. Right panel:Modulation of CV by miR-132 silencing. The administration
of antagomir-132 nanoparticles leads to deposition of antagomir-132 cargo in
blood vessel endothelial cells, resulting in silencing of miR-132. This leads to
higher levels of Ras-GAP, which, thereby, inhibits angiogenic Ras activity,
resulting in inhibition of CV.duced levels of downstream signaling products ofVEGF-A stimulation, such as active Ras in the CD31-
enriched cells (presumably blood vessel endothelial
cells) than controls (Figure 7).
An unsolved issue, however, is to explain the connec-
tion between the virus infection and the VEGF-A produc-
tion. Some have advocated that virus-infected cells them-
selves produce VEGF-A,27 but perhaps the more
common circumstance is VEGF-A production by several
uninfected cell types in response to one or more agonists
generated as a consequence of the infection. These ago-
nists include proinflammatory cytokines, such as IL-6,
that can cause inflammatory cell types to produce
VEGF-A in our previous study.28 An additional cytokine
that could participate in causing VEGF-A production is
IL-17A. This cytokine is produced in the cornea after HSV
infection, mainly by innate immune cells in initial stages
and, later on, by CD4 Th17 T cells.29 In support of IL-17A
as involved in miR-132 production, we showed that levels
of miR-132 produced in WT mice after infection were
higher than those in animals unable to respond to IL-17A
because they lacked the IL-17A receptor. Accordingly,
IL-17RKO animals displayed more miR-132 target, Ras-
GAP, in corneas after HSV infection.
Our observation that miR-132 appears to be involved
in orchestrating CV in an infectious disease situation is a
novel finding. It leads to the question about the therapeu-
tic potential of targeting miRNAs as a means to control
clinical diseases. Progress on this topic has already been
accomplished in some autoimmune and neoplastic dis-
eases.30 Many studies focus on the miR-155 that is in-
volved in regulating inflammatory pathways.31 miR-155
can be up-regulated by exposure to several TLR ligands
and is overexpressed during some autoimmune dis-
eases, as well as a diverse array of immune cell can-
cers.20 Of particular interest, knockout mice exist that
lack miR-155. Such mice are resistant to experimental
autoimmune encephalomyelitis and collagen-induced ar-
thritis and generate T-cell responses that emphasize the
type 2 helper T-cell pattern.32 In preliminary studies, we
have shown that miR-155 may also be involved in the
pathogenesis of SK (unpublished results). In disease sit-
uations that involve changes in one or more species of
miRNAs, the issue will be to determine whether modulat-
ing their expression represents a more viable approach
to control inflammatory and neoplastic diseases than
other procedures. We are attempting to answer this ques-
tion in the SK system by comparing the miRNA antago-
mirs in the nanoparticles approach with other control
procedures. So far, there are no results to report. What-
ever occurs, there is at least one theoretical advantage of
targeting miR-132 to control angiogenesis. Thus, anti-
angiogenic therapies that target single pathways, such
as VEGFR signaling, often develop resistance by up-
regulating alternative angiogenic growth factors.33 This
problem can be avoided using miR-132 because it re-
moves an endogenous regulator (Ras-GAP) involved in
controlling responses to several angiogenic factors. On
the other hand, because miRNAs have multiple mRNA
targets, a potential downside of the approach could be a
crossfire effect that turns off some useful gene expres-
sion, alongside that of the gene being selected for silenc-
534 Mulik et al
AJP August 2012, Vol. 181, No. 2ing. The results of future studies will reveal when situa-
tions are most appropriate for the use of miRNA for
therapy.
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